Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments for age-related macular degeneration, according to a press release.
The collaboration will combine Character Bio’s AI-powered analytical engine and patient data platform with Bausch + Lomb’s “extensive expertise in ophthalmology” to drive development, according to the release. In addition to an upfront payment and annual research funding from Bausch + Lomb, Character Bio is eligible for development and sales-related milestone payments as well as